| Project/Area Number |
17591505
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Tokyo Medical and Dental University |
|---|
Principal Investigator |
MAEHARA Taketoshi Tokyo Medical and Dental University, Medical Hospital, Lecturer, 医学部附属病院, 講師 (40211560)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NARIAI Tadashi Tokyo Medical and Dental University, Medical Hospital, Lecturer, 医学部附属病院, 講師 (00228090)
SATO Katsushige Tokyo Medical and Dental University, Graduate School, Lecturer, 大学院医歯学総合研究科, 講師 (80291342)
SASAKI Toru Tokyo Metropolitan Institute of Gerontology, Research Team for Molecular Biomarker, Study member, 老化ゲノムマーカー研チーム, 研究員 (30158927)
|
|---|
| Project Period (FY) |
2005 – 2006
|
| Project Status |
Completed (Fiscal Year 2006)
|
| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2006: ¥1,800,000 (Direct Cost: ¥1,800,000)
Fiscal Year 2005: ¥1,700,000 (Direct Cost: ¥1,700,000)
|
|---|
| Keywords | epilepsy / inhibitory receptor / human brain slice / navigation / positron CT |
|---|
| Research Abstract |
1) Seventeen patients with Intractable epilepsy underwent image-guided surgery with positron emission CT (PET). They included 10 patients with temporal lobe epilepsy and 7 patients with extra-temporal lobe epilepsy. MRI demonstrated organic lesions in 14 patients. All the patients underwent F18-fluorodeoxyglucose (FDG)-PET study, 13 patients underwent C11-flumazenil (FMZ), that is an antagonist of central beuzodlazepine receptor, and 3 patients underwent PET study using an antagonist of peripheral beuzodiazepine receptor.
2) The extent of FMZ-PET abnormalities was significantly larger than the corresponding structural lesions, but it was significantly smaller than the areas with decreased FDG-PET uptake. Patients with cavernous anglomas had significantly smaller areas with decreased uptake both of FMZ and FDG-PET than those with brain tumors. (Reported in the annual meetings of American epilepsy society in 2005).
3) PET study indicated that the uptake of an antagonist of peripheral benzodiazepine receptor tended to increase in the epileptogenic areas.
4) In 6 patients, we compared the results of FMZ-PET and IMZ-SPECT, which is also an antagonist of central benzodiazepine receptor. Low-uptake areas in FMZ-PET are not always concordant with those of IMZ-SPECT. However, in cases with cortical dysgenesis, low-uptake areas on FMZ-PET are well concordant with those of IMZ-SPECT.
5) In human slice studies we demonstrated that the uptake rates of FDG in human gray matter expressed as a high K(+)/control ratio, closely matched that observed by FDG-PET.(Brain Res. 2007;1142:19-27.)
|
